Hepatitis C

Lancet

Volumn 351, Issue 9099, 1998, Pages 351-355

  Di Bisceglie, Adrian M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; AMINOTRANSFERASE; HEPATITIS C ANTIBODY; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; RIBAVIRIN; URSODEOXYCHOLIC ACID; VIRUS PROTEIN; VIRUS RNA;

AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LIVER DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHORT SURVEY; VIRUS TRANSMISSION;

EID: 0032583933     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)07361-3     Document Type: Review

References (37)

1. 1 Choo Q-L, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
2. 2 Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15: 5-14.
3. 3 Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685-90.
4. 4 Conry-Cantilena C, Van Raden M, Gibble J, et al. Routes of infection, viremia and liver disease in asymptomatic individuals with hepatitis C virus infection. N Engl J Med 1996; 334: 1691-96.
5. 5 Alter MJ, Hadler SC, Judson FN et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264: 2231-35.
6. 6 Arthur RR, Hassan NF, Abdallah MY, et al. Hepatitis C antibody prevalence in blood donors in different governates in Egypt. Trans R Soc Trop Med Hyg 1997; 91: 271-74.
7. 7 Houghton M, Weiner A, Han J et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991; 14: 381-88.
8. 8 Linnen J, Wages J, Zhang-Keck Z-Y, et al. Molecular cloning and disease association of hepatitis G virus: transfusion-transmissible agent. Science 1996; 271: 505-09.
9. 9 Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 570-74.
10. 10 Davidson F, Simmonds P, Ferguson JC, et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol 1995; 76: 1197-1204.
11. 11 Feinman SV, Berris B, Bojraski S. Posttransfusion hepatitis in Toronto, Canada. Gastroenterology 1988; 95: 464-69.
12. 12 Di Bisceglie AM, Goodman ZD, Ishak KG, et al: Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.
13. 13 Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-11.
14. 14 Shakil O, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibodies to hepatitis C virus: clinical, biochemical, virological and histological features. Ann Intern Med 1995; 123: 330-37.
15. 15 Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-39.
16. 16 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
17. 17 National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26: 2S-10S.
18. 18 Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26: 34S-8S.
19. 19 Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328: 465-70.
20. 20 DeCastro M, Sanchez J, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17: 551-57.
21. 21 Silva AE, Hosein B, Boyle RW, et al. Diagnosis of chronic hepatitis C: comparison of immunoassays and the polymerase chain reaction. Am J Gastroenterol 1994; 89: 493-98.
22. 22 Nolte FS, Thurmond C, Fried M. Preclinical evaluation of Amplicor hepatitis C test for detection of hepatitis C virus RNA. J Clin Microbiol 1995; 33: 1775-78.
23. 23 Alter HJ, Sanchez-Pescador R, Urdea MS, et al. Evaluation of branched DNA signal amplification for the detection of hepatitis C virus RNA. J Viral Hepat 1995; 2: 121-32.
24. 24 Shindo M, Di Bisceglie AM, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-04.
25. 25 Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-19.
26. 26 Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 1986; 315: 1575-78.
27. 27 Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89.
28. 28 Marcellin P, Boyer N, De Gott C, et al. Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver 1994; 14: 302-07.
29. 29 Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62.
30. 30 Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-65.
31. 31 Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-56.
32. 32 Lau JYN, Mizokami M, Ohno T, Diamond DA, Kniffen J, Davis GL. Discrepancy between biochemical and virological responses to interferon-α in chronic hepatitis C. Lancet 1993; 342: 1208-09.
33. 33 Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.
34. 34 Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-17.
35. 35 Reichard O, Norkrans G, Frydén A, et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
36. 36 Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 343-55.
37. 37 Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20:1137-13.